Literature DB >> 15849507

Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases.

Timothy M Pawlik1, Charles R Scoggins, Daria Zorzi, Eddie K Abdalla, Axel Andres, Cathy Eng, Steven A Curley, Evelyne M Loyer, Andrea Muratore, Gilles Mentha, Lorenzo Capussotti, Jean-Nicolas Vauthey.   

Abstract

OBJECTIVE: To evaluate the influence of surgical margin status on survival and site of recurrence in patients treated with hepatic resection for colorectal metastases.
METHODS: Using a multicenter database, 557 patients who underwent hepatic resection for colorectal metastases were identified. Demographics, operative data, pathologic margin status, site of recurrence (margin, other intrahepatic site, extrahepatic), and long-term survival data were collected and analyzed.
RESULTS: On final pathologic analysis, margin status was positive in 45 patients, and negative by 1 to 4 mm in 129, 5 to 9 mm in 85, and > or =1 cm in 298. At a median follow-up of 29 months, the 1-, 3-, and 5-year actuarial survival rates were 97%, 74%, and 58%; median survival was 74 months. Tumor size > or =5 cm, >3 tumor nodules, and carcinoembryonic antigen level >200 ng/mL predicted poor survival (all P < 0.05). Median survival was 49 months in patients with positive margins and not yet reached in patients with negative margins (P = 0.01). After hepatic resection, 225 (40.4%) patients had recurrence: 21 at the surgical margin, 56 at another intrahepatic site, 82 at an extrahepatic site, and 66 at both intrahepatic and extrahepatic sites. Patients with negative margins of 1 to 4 mm, 5 to 9 mm, and > or =1 cm had similar overall recurrence rates (P > 0.05). Patients with positive margins were more likely to have surgical margin recurrence (P = 0.003). Adverse preoperative biologic factors including tumor number greater than 3 (P = 0.01) and a preoperative CEA level greater than 200 ng/mL (P = 0.04) were associated with an increased risk of positive surgical margin.
CONCLUSIONS: A positive margin after resection of hepatic colorectal metastases is associated with adverse biologic factors and increased risk of surgical-margin recurrence. The width of a negative surgical margin does not affect survival, recurrence risk, or site of recurrence. A predicted margin of <1 cm after resection of hepatic colorectal metastases should not be used as an exclusion criterion for resection.

Entities:  

Mesh:

Year:  2005        PMID: 15849507      PMCID: PMC1357126          DOI: 10.1097/01.sla.0000160703.75808.7d

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  38 in total

1.  The Brisbane 2000 terminology of liver anatomy and resections. HPB 2000; 2:333-39.

Authors:  Yeung Yuk Pang
Journal:  HPB (Oxford)       Date:  2002       Impact factor: 3.647

2.  Surgical margin in hepatic resection for colorectal metastasis: a critical and improvable determinant of outcome.

Authors:  B Cady; R L Jenkins; G D Steele; W D Lewis; M D Stone; W V McDermott; J M Jessup; A Bothe; P Lalor; E J Lovett; P Lavin; D C Linehan
Journal:  Ann Surg       Date:  1998-04       Impact factor: 12.969

3.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

4.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

Review 5.  Complication, local recurrence, and survival rates after radiofrequency ablation for hepatic malignancies.

Authors:  Courtney L Scaife; Steven A Curley
Journal:  Surg Oncol Clin N Am       Date:  2003-01       Impact factor: 3.495

6.  Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection.

Authors:  Norihiro Kokudo; Yoshio Miki; Sachiko Sugai; Akio Yanagisawa; Yo Kato; Yoshihiro Sakamoto; Junji Yamamoto; Toshiharu Yamaguchi; Tetsuichiro Muto; Masatoshi Makuuchi
Journal:  Arch Surg       Date:  2002-07

7.  Resection of hepatic metastases from colorectal cancer.

Authors:  M A Adson; J A van Heerden; M H Adson; J S Wagner; D M Ilstrup
Journal:  Arch Surg       Date:  1984-06

8.  Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors.

Authors:  T J Gayowski; S Iwatsuki; J R Madariaga; R Selby; S Todo; W Irish; T E Starzl
Journal:  Surgery       Date:  1994-10       Impact factor: 3.982

9.  Improved survival after resection of colorectal liver metastases.

Authors:  G M Fuhrman; S A Curley; D C Hohn; M S Roh
Journal:  Ann Surg Oncol       Date:  1995-11       Impact factor: 5.344

Review 10.  Development of new agents for the treatment of advanced colorectal cancer.

Authors:  Nancy L Lewis; Neal J Meropol
Journal:  Clin Colorectal Cancer       Date:  2003-11       Impact factor: 4.481

View more
  356 in total

1.  Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841.

Authors:  Jan Franko; Qian Shi; Charles D Goldman; Barbara A Pockaj; Garth D Nelson; Richard M Goldberg; Henry C Pitot; Axel Grothey; Steven R Alberts; Daniel J Sargent
Journal:  J Clin Oncol       Date:  2011-12-12       Impact factor: 44.544

2.  Clinical risk score can be used to select patients for staging laparoscopy and laparoscopic ultrasound for colorectal liver metastases.

Authors:  A J Shah; J Phull; M D Finch-Jones
Journal:  World J Surg       Date:  2010-09       Impact factor: 3.352

Review 3.  The surgical treatment of hepatic metastases in colorectal carcinoma.

Authors:  Ulf Peter Neumann; Daniel Seehofer; Peter Neuhaus
Journal:  Dtsch Arztebl Int       Date:  2010-05-14       Impact factor: 5.594

4.  Percutaneous stereotactic radiofrequency ablation of colorectal liver metastases.

Authors:  Reto Bale; Gerlig Widmann; Peter Schullian; Marion Haidu; Georg Pall; Alexander Klaus; Helmut Weiss; Matthias Biebl; Raimund Margreiter
Journal:  Eur Radiol       Date:  2011-11-10       Impact factor: 5.315

5.  CT-guided radiofrequency ablation as a salvage treatment of colorectal cancer hepatic metastases developing after hepatectomy.

Authors:  Constantinos T Sofocleous; Elena N Petre; Mithat Gonen; Karen T Brown; Stephen B Solomon; Anne M Covey; William Alago; Lynn A Brody; Raymond H Thornton; Michael D'Angelica; Yuman Fong; Nancy E Kemeny
Journal:  J Vasc Interv Radiol       Date:  2011-04-22       Impact factor: 3.464

Review 6.  Current treatment for colorectal liver metastases.

Authors:  Evangelos P Misiakos; Nikolaos P Karidis; Gregory Kouraklis
Journal:  World J Gastroenterol       Date:  2011-09-28       Impact factor: 5.742

Review 7.  Hepatic resection for colorectal metastases: the impact of surgical margin status on outcome.

Authors:  George A Poultsides; Richard D Schulick; Timothy M Pawlik
Journal:  HPB (Oxford)       Date:  2010-02       Impact factor: 3.647

Review 8.  Complications of intraoperative radiofrequency ablation of liver metastases.

Authors:  Tsiriniaina Razafindratsira; Milène Isambert; Serge Evrard
Journal:  HPB (Oxford)       Date:  2010-12-07       Impact factor: 3.647

9.  Treatment of colorectal cancer with unresectable synchronous liver-only metastases with combined therapeutic modalities.

Authors:  Yunlong Cui; Huikai Li; Qiang Wu; Ti Zhang; Dalu Kong; Tianqiang Song; Tao Ru; Ping Chen; Qiang Li
Journal:  J Gastrointest Surg       Date:  2010-10-05       Impact factor: 3.452

Review 10.  Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer.

Authors:  Young Seok Seo; Mi-Sook Kim; Hyung-Jun Yoo; Won-Il Jang
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.